Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.
With over 150 lawyers focused on serving over 600 life sciences clients, our integrated, full service life sciences team offers deep transactional expertise drawing on firm resources spread across the globe. Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. In the past two years, Goodwin has advised twenty three biotechnology issuers on their IPOs totaling an aggregate of $4.1 billion.
2022
Company Name |
Therapeutic Focus; Treatment Type |
Underwriters |
IPO Date |
Offer Price to the Public |
Aggregate Offering Raise |
Original Price Range |
Goodwin Participation,
|
| PepGen Inc. (NASDAQ: PEPG) |
Neuromuscular and Neurologic Diseases; Therapeutics | BofA Securities Stifel SVB Securities Wedbush Securities |
05/05/2022 S-1 |
$12.00 | $108 million | $13 – $15 | Issuer |
| AN2 Therapeutics (NASDAQ: ANTX) |
Rare, Chronic and Serious Infectious Diseases; Therapeutics | Oppenheimer & Co. Cowen & Co. SVB Leerink Evercore |
03/24/2022 S-1 |
$15.00 | $69 million | $14 – $16 | |
| Arcellx, Inc. (NASDAQ: ACLX) |
Cancer; Cell Therapies | Barclays Capital BofA Securities SVB Leerink William Blair & Co. |
02/04/2022 S-1 |
$15.00 | $142.31 million | $15 – $17 | |
| Vigil Neuro (NASDAQ: VIGL) |
Neurodegenerative Diseases; Cell Therapies | Morgan Stanley Jefferies Stifel Guggenheim |
01/11/2022 S-1 |
$14.00 | $98 million | $14 – $16 | Issuer |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) |
Neurodegenerative Diseases; Therapeutics | Evercore Goldman Sachs H.C. Wainwright SVB Leerink |
01/07/2022 S-1 |
$19.00 | $190 million | $18 – $20 | Issuer |
| Cincor Pharma (NASDAQ: CINC) |
Neurodegenerative Diseases; Therapeutics | Evercore Jefferies Morgan Stanley Oppenheimer |
01/06/2022 S-1 |
$17.00 | $193.60 million | $15 – $17 |
2021
Company Name |
Therapeutic Focus; Treatment Type |
Underwriters |
IPO Date |
Offer Price to the Public |
Aggregate Offering Raise |
Original Price Range |
Goodwin Participation,
|
| Vaxxinity (NASDAQ: VAXX) |
Chronic Diseases; Vaccines | BofA Securities Evercore Jefferies |
11/11/2021 S-1 |
$13.00 | $78 million | $14 – $16 | |
| IO Biotech (NASDAQ: IOBT) |
Cancer; Immunotherapies | Cowen & Co. Jefferies Kempen & Co. Morgan Stanley & Co. |
11/4/2021 S-1 |
$14.00 | $115.11 million | $14 – $17 | |
| LianBio (NASDAQ: LIAN) |
Cardiovascular; Oncology; Therapeutics | BofA Securities Goldman Sachs Jefferies Raymond James & Assoc. |
11/1/2021 S-1 |
$16.00 | $325 million | $15 – $17 | |
| Aura Biosciences (NASDAQ: AURA) |
Cancer; Drug Discovery | BTIG Cowen & Co. Evercore SVB Leerink |
10/29/2021 S-1 |
$14.00 | $75.60 million | $14 – $16 | Issuer |
| Xilio Therapeutics (NASDAQ: XLO) |
Cancer; Biologics | Cowen & Co. Guggenheim Morgan Stanley & Co. Raymond James & Assoc. |
10/22/2021 S-1 |
$16.00 | $117.65 million | $16 – $18 | |
| Ventyx Biosciences, Inc. (NASDAQ: VTYX) |
Autoimmune; Inflammatory Diseases | Evercore Jefferies LifeSci Capital Piper Sandler |
10/20/2021 S-1 |
$16.00 | $174.30 million | $15 – $17 | |
| Pyxis Oncology (NASDAQ: PYXS) |
Cancer; Biologics; Antibodies | BofA Securities Credit Suisse Jefferies LifeSci Capital William Blair & Co. |
10/7/2021 S-1 |
$16.00 | $168 million | $14 – $16 | |
| Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) |
Cancer; Transformative Targeted Therapies | SVB Leerink Cantor Fitzgerald Jefferies Wedbush Securities |
10/6/2021 S-1 |
$16.00 | $160 million | $14 – $16 | |
| Dice Therapeutics (NASDAQ: DICE) |
Oral Therapeutics; Chronic Diseases | SVB Leerink Evercore BofA Securities |
9/14/2021 S-1 |
$17.00 | $204 million | $15 – $17 | |
| Eliem Therapeutics (NASDAQ: ELYM) |
CNS Disorders; Small Molecules | SVB Leerink Evercore Stifel Nicolaus Guggenheim |
8/9/2021 S-1 |
$12.50 | $92 million | $17 – $19 | |
| Adagio Therapeutics (NASDAQ: ADGI) |
Infectious Diseases; Biologics | Morgan Stanley Jefferies Stifel Nicolaus Guggenheim |
8/5/2021 S-1 |
$17 | $355.8 million | $16 – $18 | |
| Rani Therapeutics (NASDAQ: RANI) |
Rare Diseases; Drug Delivery | BofA Securities Stifel Nicolaus Cantor Fitzgerald Canaccord Genuity |
7/30/2021 S-1 |
$11 | $73.3 million | $14 – $16 | Underwriters |
| Immuneering (NASDAQ: IMRX) |
Cancer; Small Molecules | Morgan Stanley Jefferies Cowen & Co. Guggenheim |
7/30/2021 S-1 |
$15 | $129.4 million | $14 – $16 | |
| Omega Therapeutics (NASDAQ: OMGA) |
Cancer; Biologics | Goldman Sachs Jefferies Piper Sandler |
7/30/2021 S-1 |
$17 | $125.8 million | $16 – $18 | Underwriters |
| Tenaya Therapeutics (NASDAQ: TNYA) |
Heart Diseases; Gene Therapy | Morgan Stanley Cowen & Co. Piper Sandler |
7/30/2021 S-1 |
$15 | $207 million | $14 – $16 | |
| Nuvalent (NASDAQ: NUVL) |
Cancer; Small Molecules | J.P. Morgan Cowen Piper Sandler |
7/28/2021 S-1 |
$17 | $190.6 million | $16 – $18 | Issuer |
| Icosavax (NASDAQ: ICVX) |
Infectious Diseases; Vaccines | Jefferies Cowen Evercore William Blair |
7/28/2021 S-1 |
$15 | $209.3 million | $14 – $16 | |
| Rallybio (NASDAQ: RLYB) |
Rare Diseases; Biologics | Jefferies Cowen Evercore |
7/28/2021 S-1 |
$13 | $92.7 million | $13 – $15 | |
| Candel Therapeutics (NASDAQ: CADL) |
Cancer; Biologics | Jefferies Credit Suisse BMO Capital Markets UBS |
7/26/2021 S-1 |
$8 | $72 million | $13 – $15 | Issuer |
| Caribou Biosciences (NASDAQ CRBU) |
Cancer; Gene Therapy | BofA Securities Citigroup SVB Leerink |
7/22/2021 S-1 |
$16 | $304 million | $14 – $16 | |
| HCW Biologics (NASDAQ: HCWB) |
Cancer; Biologics | EF Hutton | 7/19/2021 S-1 |
$8 | $56 million | $8 – $10 | |
| Imago BioSciences (NASDAQ: IMGO) |
Cancer; Small Molecules | Jefferies Cowen & Co. Stifel Nicolaus Guggenheim |
7/15/2021 S-1 |
$16 | $134.4 million | $14 – $16 | |
| TScan Therapeutics (NASDAQ: TCRX) |
Cancer; Cell Therapy | Morgan Stanley Jefferies Cowen & Co. Barclays Capital |
7/15/2021 S-1 |
$15 | $100 million | $15 – $17 | |
| Erasca (NASDAQ: ERAS) |
Cancer; Small Molecules | J.P. Morgan Morgan Stanley BofA Securities Evercore Guggenheim |
7/15/2021 S-1 |
$16 | $345 million | $14 – $16 | |
| Acumen Pharmaceuticals (NASDAQ: ABOS) | CNS Disorders; Antibodies | BofA Securities Credit Suisse Stifel Nicolaus UBS |
6/30/2021 S-1 |
$16 | $160 million | $14 – $16 | |
| Aerovate Therapeutics (NASDAQ: AVTE) |
Heart diseases; Drug Delivery | Jefferies Cowen & Co. Evercore Wedbush PacGrow |
6/29/2021 S-1 |
$14 | $139.8 million | $13 – $15 | Issuer |
| GH Research (NASDAQ: GHRS) |
CNS Disorders; Small Molecules | Cowen & Co. Stifel Nicolaus Canaccord Genuity JMP Securities |
6/24/2021 F-1 |
$16 | $160 million | $14 – $16 | |
| Graphite Bio (NASDAQ: GRPH) |
Rare Diseases; Gene Therapy | Morgan Stanley BofA Securities Cowen & Co. SVB Leerink |
6/24/2021 S-1 |
$17 | $273.7 million | $15 – $17 | Issuer |
| Elevation Oncology (NASDAQ: ELEV) |
Cancer; Antibodies | J.P. Morgan Cowen & Co. SVB Leerink Wedbush PacGrow |
6/24/2021 S-1 |
$16 | $100 million | $15 – $17 | |
| Monte Rosa Therapeutics (NASDAQ: GLUE) |
Cancer; Small Molecules | J.P. Morgan Cowen & Co. Piper Sandler Guggenheim |
6/23/2021 S-1 |
$19 | $222.3 million | $17 – $19 | Issuer |
| Ambrx Biopharma (NYSE: AMAM) |
Cancer; Biologics | Goldman Sachs BofA Securities Cowen & Co. |
6/17/2021 F-1 |
$18 | $126 million | $17 – $19 | Underwriters |
| atai Life Sciences (NASDAQ: ATAI) |
CNS Disorders; Small Molecules | Credit Suisse Citigroup Cowen & Co. Berenberg Capital Markets Cantor Fitzgerald RBC Capital Markets Canaccord Genuity |
6/17/2021 S-1 |
$15 | $225 million | $13 – $15 | |
| Cyteir Therapeutics (NASDAQ: CYT) |
Cancer; Small Molecules | J.P. Morgan Morgan Stanley BofA Securities Wedbush PacGrow |
6/17/2021 S-1 |
$18 | $133.3 million | $16 – $18 | |
| Century Therapeutics (NASDAQ: IPSC) |
Cancer; Cell Therapy | J.P. Morgan BofA Securities SVB Leerink Piper Sandler |
6/17/2021 S-1 |
$20 | $242.7 million | $18 – $20 | |
| Lyell Immunopharma (NASDAQ: LYEL) |
Cancer; Cell Therapy | Goldman Sachs BofA Securities J.P. Morgan Morgan Stanley |
6/16/2021 S-1 |
$17 | $425 million | $16 – $18 | |
| Verve Therapeutics (NASDAQ: VERV) |
Heart Diseases; Gene Therapy | J.P. Morgan Jefferies Guggenheim William Blair |
6/16/2021 S-1 |
$19 | $306.7 million | $16 – $18 | |
| Molecular Partners (NASDAQ: MOLN) |
Infectious Diseases; Biologics | J.P. Morgan SVB Leerink Cowen & Co. RBC Capital Markets Kempen & Co. |
6/15/2021 F-1 |
$21.25 | $63.8 million | $27.14 | |
| Janux Therapeutics (NASDAQ: JANX) |
Cancer; Biologics | BofA Securities Cowen & Co. Evercore H.C. Wainwright |
6/10/2021 S-1 |
$17 | $222.9 million | $15-$17 | |
| Centessa Pharmaceuticals (NASDAQ: CNTA) |
Cancer; Small Molecules | Morgan Stanley Goldman Sachs Jefferies Evercore |
5/27/2021 S-1 |
$20 | $379.5 million | $18 – $20 | Issuer |
| Day One Biopharmaceuticals (NASDAQ: DAWN) |
Cancer; Small Molecules | J.P. Morgan Cowen & Co. Piper Sandler Wedbush PacGrow |
5/26/2021 S-1 |
$16 | $184 million | $14 – $16 | |
| Talaris Therapeutics (NASDAQ: TALS) |
Immune Diseases; Cell Therapy | Morgan Stanley SVB Leerink Evercore Guggenheim |
5/6/2021 S-1 |
$17 | $150 million | $16 – $18 | Issuer |
| Valneva (NASDAQ: VALN) |
Infectious Diseases; Vaccines | Goldman Sachs Jefferies Guggenheim Bryan, Garnier & Co. |
5/6/2021 F-1 |
$26.41 | $107.6 million | $24.04 – $28.85 | Underwriters |
| Werewolf Therapeutics (NASDAQ: HOWL) |
Cancer; Biologics | Jefferies SVB Leerink Evercore H.C. Wainwright |
4/29/2021 S-1 |
$16 | $120 million | $15 – $17 | |
| Vaccitech (NASDAQ: VACC) |
Infectious Diseases; Vaccines | Morgan Stanley Jefferies Barclays William Blair H.C. Wainwright |
4/29/2021 S-1 |
$17 | $110.5 million | $16 – $18 | Issuer |
| Impel NeuroPharma (NASDAQ: IMPL) |
CNS Disorders; Drug Delivery | Cowen & Co. Guggenheim Wedbush PacGrow |
4/22/2021 S-1 |
$15 | $80 million | $14 – $16 | |
| Rain Therapeutics (NASDAQ: RAIN) |
Cancer; Small Molecules | Goldman Sachs Citigroup Piper Sandler Guggenheim |
4/22/2021 S-1 |
$17 | $125 million | $16 – $18 | |
| Biomea Fusion (NASDAQ: BMEA) |
Cancer; Small Molecules | J.P. Morgan Jefferies Piper Sandler |
4/15/2021 S-1 |
$17 | $153 million | $15 – $17 | |
| Recursion Pharmaceuticals (NASDAQ: RXRX) |
Rare Diseases; Small Molecules | Goldman Sachs J.P. Morgan BofA Securities SVB Leerink Allen & Company KeyBanc Capital Markets |
4/15/2021 S-1 |
$18 | $501.8 million | $16 – $18 | |
| Reneo Pharmaceuticals (NASDAQ: RPHM) |
Rare Diseases; Small Molecules | Jefferies SVB Leerink Piper Sandler |
4/8/2021 S-1 |
$15 | $93.8 million | $15 – $17 | |
| VectivBo (NASDAQ: VECT) |
Rare Diseases; Biologics | BofA Securities SVB Leerink Credit Suisse LifeSci Capital |
4/8/2021 F-1 |
$17 | $146.6 million | $16 – $18 | |
| Achilles Therapeutics (NASDAQ: ACHL) |
Cancer; Cell Therapy | J.P. Morgan BofA Securities Piper Sandler Chardan Capital Markets Oppenheimer Kempen & Co |
3/30/2021 F-1 |
$18 | $175.5 million | $17 – $19 | Issuer |
| Design Therapeutics (NASDAQ: DSGN) |
Rare Diseases; Small Molecules | Goldman Sachs SVB Leerink Piper Sandler |
3/25/2021 S-1 |
$20 | $276 million | $18 – $20 | |
| Edgewise Therapeutics (NASDAQ: EWTX) |
Rare Diseases; Small Molecules | J.P. Morgan Goldman Sachs SVB Leerink |
3/25/2021 S-1 |
$16 | $202.4 million | $14 – $16 | |
| Ikena Oncology (NASDAQ: IKNA) |
Cancer; Small Molecules | Jefferies Cowen & Co. Credit Suisse William Blair |
3/25/2021 S-1 |
$16 | $143.8 million | $15 – $17 | Issuer |
| LAVA Therapeutics (NASDAQ: LVTX) |
Cancer; Antibodies | J.P. Morgan Jefferies SVB Leerink |
3/24/2021 F-1 |
$15 | $100.5 million | $14 – $16 | |
| Connect Biopharma (NASDAQ: CNTB) |
Immune Diseases; Antibodies | Jefferies SVB Leerink Piper Sandler China International Capital Corporation |
3/18/2021 F-1 |
$17 | $219.9 million | $15 – $17 | |
| Instil Bio (NASDAQ: TIL) |
Cancer; Cell Therapy | Morgan Stanley Jefferies Cowen & Co. |
3/18/2021 S-1 |
$20 | $368 million | $17 – $19 | |
| Finch Therapeutics (NASDAQ: FNCH) |
Immune Diseases; Biologics | BofA Securities Jefferies Evercore |
3/18/2021 S-1 |
$17 | $127.5 million | $15 – $17 | Underwriters |
| Prometheus Biosciences (NASDAQ: RXDX) |
Immune Diseases; Antibodies | SVB Leerink Credit Suisse Stifel Nicolaus Guggenheim |
3/11/2021 S-1 |
$19 | $218.5 million | $16 – $18 | |
| Longboard Pharmaceuticals (NASDAQ: LBPH) |
CNS Disorders; Small Molecules | Citigroup Evercore Guggenheim Cantor Fitzgerald |
3/11/2021 S-1 |
$16 | $80 million | $14 – $16 | |
| NexImmune (NASDAQ: NEXI) |
Cancer; Cell Therapy | Barclays Capital Cantor Fitzgerald Raymond James Allen & Company |
2/11/2021 S-1 |
$17 | $126.5 million | $15 – $17 | |
| Decibel Therapeutics (NASDAQ: DBTX) |
Ear Diseases; Gene Therapy | Citigroup SVB Leerink BMO Capital Markets Barclays Capital |
2/11/2021 S-1 |
$18 | $127 million | $16 – $18 | Underwriter |
| Adagene (NASDAQ: ADAG) |
Cancer; Antibodies | Goldman Sachs (Asia) Morgan Stanley Jefferies China Renaissance Securities (Hong Kong) |
2/08/2021 F-1 |
$19 | $161 million | $17 – $19 | |
|
Vor Biopharma
|
Cancer; Cell Therapy | Goldman Sachs Evercore Barclays Capital Stifel Nicolaus |
2/05/2021 S-1 |
$18 | $203.4 million | $16 – $18 | |
|
Angion Biomedica
|
Kidney Diseases; Small Molecules | Cowen & Co. Stifel Nicolaus H.C. Wainwright Oppenheimer |
2/04/2021 S-1 |
$16 | $92 million | $14 – $16 | |
|
Bolt Biotherapeutics
|
Cancer; Biologics | Morgan Stanley SVB Leerink Stifel Nicolaus Guggenheim |
2/04/2021 S-1 |
$20 | $264.5 million | $16 – $18 | |
|
Immunocore
|
Cancer; Cell Therapy | Goldman Sachs J.P. Morgan Jefferies |
2/04/2021 F-1 |
$26 | $297.1 million | $23 – $25 | |
|
|
Rare Diseases; Small Molecules | Morgan Stanley BofA Securities Sunrise Securities Oppenheimer Kempen & Co |
2/04/2021 F-1 |
$20 | $190.2 million | $17 – $19 | |
|
Terns Pharmaceuticals
|
Liver Diseases; Small Molecules | J.P. Morgan Goldman Sachs Cowen & Co. |
2/04/2021 S-1 |
$17 | $146.6 million | $15 – $17 | |
|
Sensei Biotherapeutics
|
Cancer; Biologics | Citigroup Piper Sandler Berenberg Capital Markets Oppenheimer |
2/03/2021 S-1 |
$19 | $152.6 million | $16 – $18 | Underwriters |
|
Landos Biopharma
|
Immune Diseases; Small Molecules | J.P. Morgan Jefferies SVB Leerink Raymond James |
2/03/2021 S-1 |
$16 | $100 million | $15 – $17 | |
|
Sana Biotechnology
|
Cancer; Cell Therapy | Morgan Stanley Goldman Sachs J.P. Morgan BofA Securities |
2/03/2021 S-1 |
$25 | $675.6 million | $20 – $23 | |
| Cullinan Management (NASDAQ: CGEM) |
Cancer; Biologics | Morgan Stanley SVB Leerink Evercore H.C. Wainwright |
1/07/2021 S-1 |
$21 | $287.4 million | $17 – $19 | Issuer |
| Gracell Biotechnologies (NASDAQ: GRCL) |
Cancer; Cell Therapy | Citigroup Jefferies Piper Sandler Wells Fargo |
1/07/2021 F-1 |
$19 | $209 million | $16 – $18 |
2020
Company Name |
Company
|
Underwriters |
IPO Date |
Offer Price to the Public |
Aggregate Offering Raise |
Original Price Range |
Goodwin Participation,
|
| BioAtla (NASDAQ: BCAB) |
Therapies for solid tumor cancer | J.P. Morgan Jefferies Credit Suisse |
12/15/2020 S-1 |
$18 | $217.4 million | $15 – $17 | |
| AbCellera Biologics (NASDAQ: ABCL) |
AI-powered drug discovery platform | Credit Suisse Sifel Nicolaus Berenberg Capital Markets SVB Leerink BMO Capital Markets |
12/10/2020 S-1 |
$20 | $555.5 million | $14-$17 | Issuer |
| 4D Molecular Therapeutics (NASDAQ: FDMT) |
Gene therapies to treat diseases | Goldman Sachs BofA Securities Evercore |
12/10/2020 S-1 |
$23 | $222 million | $20 – $22 | |
| Nanobiotix (NASDAQ: NBTX) |
Nanotech to help treat cancer | Jefferies Evercore UBS |
12/10/2020 F-1 |
$11.14 | $100.4 million | $14.69 | |
| Seer (NASDAQ: SEER) |
Protein profiling technologies | J.P. Morgan Morgan Stanley BofA Securities Cowen & Co. |
12/03/2020 S-1 |
$19 | $201.3 million | $16-$18 | |
| Sigilon Therapeutics (NASDAQ: SGTX) |
Therapies for chronic diseases | Morgan Stanley Jefferies Barclays Capital Canaccord Genuity |
12/03/2020 S-1 |
$18 | $144.9 million | $17 – $19 | |
| Silverback Therapeutics (NASDAQ: SBTX) | Tissue targeted therapeutics for cancer | Goldman Sachs SVB Leerink Stifel Nicolaus |
12/03/2020 S-1 |
$21 | $277.7 million | $17-$19 | |
| Kinnate Biopharma (NASDAQ: KNTE) |
Genomically defined cancer therapeutics | Goldman Sachs SVB Leerink Piper Sandler |
12/02/2020 S-1 |
$20 | $276 million | $16-$18 | |
| Maravai LifeSciences (NASDAQ: MRVI) | Products in support of biopharma R&D | Morgan Stanley Jefferies Goldman Sachs |
11/19/2020 S-1 |
$27 | $1.86 billion | $24 – $27 | |
| Olema Pharmaceuticals (NASDAQ: OLMA) | Therapies for women’s cancers | J.P. Morgan Jefferies Cowen & Co. Canaccord Genuity |
11/18/2020 S-1 |
$19 | $240.4 million | $16 – $18 | |
| Atea Pharmaceuticals (NASDAQ: AVIR) |
Antiviral therapeutics | J.P. Morgan Morgan Stanley Evercore William Blair |
10/29/2020 S-1 |
$24 | $345 million | $22 – $24 | |
| SQZ Biotechnologies (NYSE: SQZ) |
Cell therapies for cancer | BofA Securities Evercore Stifel Nicolaus BTIG |
10/29/2020 S-1 |
$16 | $81 million | $16 – $18 | Underwriter |
| Galecto (NASDAQ: GLTO) |
Therapeutics for fibrotic diseases | BofA Securities SVB Leerink Credit Suisse |
10/28/2020 S-1 |
$15 | $85 million | $14 – $16 | Issuer |
| Foghorn Therapeutics (NASDAQ: FHTX) |
Gene expression to battle cancer | Goldman Sachs Morgan Stanley Cowen & Co. |
10/22/2020 S-1 |
$16 | $120 million | $15-$17 | |
| Abcam (NASDAQ: ABCM) |
Medical reagents & diagnostics | Morgan Stanley BofA Securities SVB Leerink Lazard Freres William Blair |
10/21/2020 F-1 |
$17.50 | $180 million | $16.52 | |
| Opthea (NASDAQ: OPT) |
Therapies for retinal diseases | Citigroup SVB Leerink Oppenheimer Truist Securities |
10/16/2020 F-1 |
$13.50 | $128.2 million | $17.26 | Underwriter |
| Aligos Therapeutics (NASDAQ: ALGS) |
Therapeutics for viral and liver diseases | J.P. Morgan Jefferies Piper Sandler Cantor Fitzgerald |
10/15/2020 S-1 |
$15 | $150 million | $15-$16 | |
| Praxis Precision Medicines (NASDAQ: PRAX) |
Central nervous system therapies | Cowen & Co. Evercore Piper Sandler Wedbush PacGrow |
10/15/2020 S-1 |
$19 | $218.5 million | $16-$18 | Issuer |
| Codiak Biosciences (NASDAQ: CDAK) |
Therapeutics using exosome biology | Goldman Sachs Evercore William Blair Wedbush PacGrow |
10/13/2020 S-1 |
$15 | $82.5 million | $14-$16 | Issuer |
| Kronos Bio (NASDAQ: KRON) |
Cancer therapeutics | Goldman Sachs Jefferies Cowen & Co. Piper Sandler |
10/8/2020 S-1 |
$19 | $287.5 million | $16-$18 | |
| Shattuck Labs (NASDAQ: STTK) |
Immuno-oncology protein therapies | Citigroup Cowen & Co. Evercore Needham |
10/8/2020 S-1 |
$17 | $232.3 million | $14-$16 | |
| Spruce Biosciences (NASDAQ: SPRB) |
Endocrine disorder therapies | Cowen & Co. SVB Leerink Credit Suisse RBC Capital Markets |
10/8/2020 S-1 |
$15 | $103.5 million | $14-$16 | |
| Aziyo Biologics (NASDAQ: AZYO) |
Tissue regenerating medical products | Piper Sandler Cowen & Co. Cantor Fitzgerald Truist Securities |
10/7/2020 S-1 |
$17 | $50 million | $16-$18 | |
| C4 Therapeutics (NASDAQ: CCCC) |
Drugs to destroy target proteins | Jefferies Evercore BMO Capital Markets UBS |
10/1/2020 S-1 |
$19 | $209.76 million | $16-$18 | Issuer |
| Immunome (NASDAQ: IMNM) |
Antibody therapeutics | Ladenburg Thalmann Chardan Capital Markets |
10/1/2020 S-1 |
$12 | $44.85 million | $11-$13 | Underwriter |
| Oncorus (NASDAQ: ONCR) |
Viral immunotherapies for cancer | Jefferies Evercore Piper Sandler |
10/1/2020 S-1 |
$15 | $87 million | $14-$16 | |
| Orphazyme (NASDAQ: ORPH) |
Neurodegenerative disease therapies | BofA Securities Cowen & Co. Guggenheim Danske Markets |
9/28/2020 F-1 |
$11 | $50.17 million | $13.13 | |
| Graybug Vision (NASDAQ: GRAY) |
Medicines to treat ocular diseases | SVB Leerink Piper Sandler |
9/24/2020 S-1 |
$16 | $90 million | $15-$17 | |
| PMV Pharmaceuticals (NASDAQ: PMVP) | Tumor-agnostic cancer therapies | Goldman Sachs BofA Securities Cowen & Co. Evercore |
9/24/2020 S-1 |
$18 | $243.53 million | $16-$18 | |
| Prelude Therapeutics (NASDAQ: PRLD) | Small molecule cancer therapies | Morgan Stanley Goldman Sachs BofA Securities |
9/24/2020 S-1 |
$19 | $181.90 million | $17-$19 | |
| Taysha Gene Therapies (NASDAQ: TSHA) |
Therapies for monogenic diseases | Goldman Sachs Morgan Stanley Jefferies |
9/23/2020 S-1 |
$20 | $181 million | $18-$20 | Underwriter |
| Athira Pharma (NASDAQ: ATHA) |
Therapeutics for neurological diseases | Goldman Sachs Jefferies Stifel Nicolaus |
9/17/2020 S-1 |
$17 | $204 million | $15-$17 | |
| COMPASS Pathways (NASDAQ: CMPS) |
Psilocybin therapies for depression | Cowen & Co. Evercore Berenberg Capital Markets |
9/17/2020 F-1 |
$17 | $146.60 million | $14-$16 | Issuer |
| Dyne Therapeutics (NASDAQ: DYN) |
Therapies for genetic muscular diseases | J.P. Morgan Jefferies Piper Sandler Stifel Nicolaus |
9/16/2020 S-1 |
$19 | $268 million | $16-$18 | |
| Metacrine (NASDAQ: MTCR) |
Liver and gastrointestinal therapies | Jefferies Evercore RBC Capital Markets Canaccord Genuity |
9/15/2020 S-1 |
$13 | $85.02 million | $12-$14 | |
| Kymera Therapeutics (NASDAQ: KYMR) | Small molecule protein degraders | Morgan Stanley BofA Securities Cowen & Co. Guggenheim |
8/20/2020 S-1 |
$20 | $199.75 million | $16-$18 | Issuer |
| Harmony Biosciences (NASDAQ: HRMY) | Therapies for neurological disorders | Goldman Sachs Jefferies Piper Sandler |
8/18/2020 S-1 |
$24 | $147.62 million | $20-$23 | Underwriter |
| Inhibrx (NASDAQ: INBX) |
Protein therapies to treat cancer | Jefferies Evercore Credit Suisse |
8/18/2020 S-1 |
$17 | $136.85 million | $16-$18 | |
| CureVac (NASDAQ: CVAC) |
Messenger RNA-based therapies | BofA Securities Jefferies Credit Suisse |
8/13/2020 F-1 |
$16 | $245.33 million | $14-$16 | |
| Checkmate Pharmaceuticals (NASDAQ: CMPI) |
Therapeutics to treat cancer | BofA Securities Jefferies BMO Capital Markets |
8/06/2020 S-1 |
$15 | $75 million | $14-$16 | Issuer |
| Freeline Therapeutics (NASDAQ: FRLN) |
Gene therapies for monogenic diseases | J.P. Morgan Morgan Stanley Evercore |
8/06/2020 F-1 |
$18 | $158.82 million | $16-$18 | Underwriter |
| Acutus Medical (NASDAQ: AFIB) |
Cardiac arrhythmia treatments | J.P. Morgan BofA Securities William Blair |
8/05/2020 S-1 |
$18 | $182.64 million | $16-$18 | |
| Oak Street Health (NYSE: OSH) |
Healthcare for adults on Medicare | J.P. Morgan Goldman Sachs Morgan Stanley |
8/05/2020 S-1 |
$21 | $377.34 million | $15-$17 | |
| AlloVir (NASDAQ: ALVR) |
Allogenic T cell therapies | Morgan Stanley J.P. Morgan SVB Leerink Piper Sandler |
7/29/2020 S-1 |
$17 | $317.68 million | $16-$18 | Issuer |
| Annexon (NASDAQ: ANNX) |
Complement-mediated disorder therapies | J.P. Morgan BofA Securities Cowen & Co. |
7/23/2020 S-1 |
$17 | $288.36 million | $14-$16 | |
| Inozyme Pharma (NASDAQ: INZY) |
Treatments for abnormal mineralization | BofA Securities Cowen & Co. Piper Sandler |
7/23/2020 S-1 |
$16 | $128.8 million | $14-$16 | |
| iTeos Therapeutics (NASDAQ: ITOS) |
Immuno-oncology therapeutics | J.P. Morgan SVB Leerink Piper Sandler |
7/23/2020 S-1 |
$19 | $231.31 million | $16-$18 | Issuer |
| Nurix Therapeutics (NASDAQ: NRIX) |
Small molecule immuno-oncology agents | J.P. Morgan Piper Sandler Stifel Nicolaus |
7/23/2020 S-1 |
$19 | $240.35 million | $16-$18 | |
| ALX Oncology (NASDAQ: ALXO) |
Immuno-oncology therapies | Jefferies Credit Suisse Piper Sandler Cantor Fitzgerald |
7/16/2020 S-1 |
$19 | $185.7 million | $15-$17 | |
| Berkeley Lights (NASDAQ: BLI) |
Biotherapeutics and cell-based products | J.P. Morgan Morgan Stanley Cowen & Co. |
7/16/2020 S-1 |
$22 | $204.9 million | $16-$18 | |
| Pandion Therapeutics (NASDAQ: PAND) |
Therapeutics for autoimmune diseases | Goldman Sachs Morgan Stanley SVB Leerink BMO Capital Markets |
7/16/2020 S-1 |
$18 | $135 million | $16-$18 | Underwriter |
| Renalytix AI (NASDAQ: RNLX) |
AI-enabled in vitro diagnostics | J.P. Morgan Sitfel Nicolaus |
7/16/2020 F-1 |
$13.50 | $85.1 million | $14.22 | Underwriter |
| Relay Therapeutics (NASDAQ: RLAY) |
Small molecule therapeutics for cancer | J.P. Morgan Goldman Sachs Cowen & Co. Guggenheim |
7/15/2020 S-1 |
$20 | $460 million | $16-$18 | Issuer |
| Inventiva (NASDAQ: IVA) |
Non-alcoholic fatty liver treatments | Jefferies Stifel Nicolaus Guggenheim |
7/09/2020 F-1 |
$14.40 | $123.8 million | $13.68 | |
| NKarta (NASDAQ: NKTX) |
Natural killer cell cancer therapies | Cowen & Co. Evercore Stifel Nicolaus Mizuho |
7/09/2020 S-1 |
$18 | $289.8 million | $14-1$16 | |
| Poseida Therapeutics (NASDAQ: PSTX) |
Cell and gene therapeutics | BofA Securities Piper Sandler William Blair |
7/09/2020 S-1 |
$16 | $257.6 million | $14-$16 | |
| Akouos, Inc. NASDAQ (AKUS) |
Gene therapies for hearing loss | BofA Securities Cowen & Co. Piper Sandler |
06/25/2020 S-1 |
$17.00 | $244.37 million |
$14.00 – $16.00 |
|
| Forma Therapeutics Holdings, Inc. NASDAQ (FMTX) |
Cancer & hematologic disease therapies | Jefferies SVB Leerink Credit Suisse |
06/25/2020 S-1 |
$20.00 | $319.29 million |
$16.00 – $18.00 |
Issuer |
| PolyPid Ltd. NASDAQ (PYPD) |
Therapies to improve surgical outcomes | Barclays Capital BMO Capital Markets Raymond James |
06/25/2020 F-1 |
$16.00 | $69.00 million |
$15.00 – $17.00 |
|
| Progenity, Inc. NASDAQ (PROG) |
Molecular testing products | Piper Sandler Wells Fargo Securities |
06/19/2020 S-1 |
$15.00 | $115.00 million |
$14.00 – $16.00 |
|
| Repare Therapeutics Inc. NASDAQ (RPTX) |
Genomic-focused cancer therapies | Morgan Stanley Goldman Sachs Cowen & Co. Piper Sandler |
06/18/2020 S-1 |
$20.00 | $253.00 million |
$16.00 – $18.00 |
Underwriter |
| Genetron Holdings Limited NASDAQ (GTH) |
Cancer molecular profiling technologies | Credit Suisse China International Capital Corporation |
06/18/2020 F-1 |
$16.00 | $294.4 million |
$11.50 – $13.50 |
|
| Royalty Pharma plc NASDAQ (RPRX) |
Biopharmaceutical royalties acquisition | J.P. Morgan Morgan Stanley BofA Securities Goldman Sachs Citigroup UBS Securities |
06/15/2020 S-1 |
$28.00 | $2.5 billion |
$25.00 – $28.00 |
Underwriter |
| Avidity Biosciences, Inc. NASDAQ (RNA) |
Therapeutics to treat serious diseases | Cowen & Co. SVB Leerink Credit Suisse Wells Fargo Securities |
06/11/2020 S-1 |
$18.00 | $298.08 million |
$14.00 – $16.00 |
|
| Burning Rock Biotech Limited NASDAQ (BNR) |
Cancer therapy selection services | Morgan Stanley BofA Securities Cowen & Co. |
06/11/2020 F-1 |
$16.50 | $256.16 million |
$13.50 – $15.50 |
|
| Generation Bio Co. NASDAQ (GBIO) |
Non-viral gene therapies | J.P. Morgan Jefferies Cowen & Co. Wedbush Securities |
06/11/2020 S-1 |
$19.00 | $229.99 million |
$16.00 – $18.00 |
|
| Vaxcyte, Inc. NASDAQ (PCVX) |
Pneumococcal conjugate vaccines | BofA Securities Jefferies Evercore |
06/11/2020 S-1 |
$16.00 | $287.50 million |
$14.00 – $16.00 |
|
| Fusion Pharmaceuticals Inc. NASDAQ (FUSN) |
Radiopharmaceuticals to treat cancers | Morgan Stanley Jefferies Cowen & Co. |
06/05/2020 S-1 |
$17.00 | $244.37 million |
$14.00 – $16.00 |
Issuer |
| Legend Biotech Corporation NASDAQ (LEGN) |
Cell therapies to treat cancer | Morgan Stanley J.P. Morgan Jefferies |
06/05/2020 F-1 |
$23.00 | $487.34 million |
$18.00 – $20.00 |
|
| Applied Molecular Transport Inc. NASDAQ (AMTI) |
Oral biologic products to treat disease | BofA Securities Jefferies SVB Leerink |
06/04/2020 S-1 |
$14.00 | $177.10 million | $12.00 – $14.00 | |
| Calliditas Therapeutics NASDAQ (CALT) |
Treatment for autoimmune renal disease | Citigroup Jefferies Stifel Nicolaus |
06/04/2020 F-1 |
$19.50 | $90.00 million |
$19.77 | Issuer |
| Pliant Therapeutics, Inc. NASDAQ (PLRX) |
Fibrosis therapeutics | Citigroup Cowen & Co. Piper Sandler |
06/02/2020 S-1 |
$16.00 | $165.60 million |
$14.00- $16.00 |
Issuer |
| Inari Medical, Inc. NASDAQ (NARI) |
Thrombectomy devices | BofA Securities Morgan Stanley |
05/21/2020 S-1 |
$19.00 | $179.22 million |
$14.00 – $16.00 |
|
| ADC Therapeutics SA NASDAQ (ADCT) |
Blood cancer therapies | Morgan Stanley BofA Securities Cowen & Co. |
05/14/2020 F-1 |
$19.00 | $267.56 million |
$16.00 – $18.00 |
|
| Ayala Pharmaceuticals, Inc. NASDAQ (AYLA) |
Small molecule therapies for cancer | Citigroup Jefferies |
05/07/2020 S-1 |
$15.00 | $63.25 million |
$14.00- $16.00 |
|
| Lyra Therapeutics, Inc. NASDAQ (LYRA) |
Localized ear, nose & throat treatments | BofA Securities Jefferies William Blair |
04/30/2020 S-1 |
$16.00 | $64.40 million |
$14.00 – $16.00 |
|
| ORIC Pharmaceuticals, Inc. NASDAQ (ORIC) |
Therapies to treat cancer | J.P. Morgan Citigroup Jefferies Guggenheim |
04/23/2020 S-1 |
$16.00 | $138.00 million |
$14.00- $16.00 |
|
| Keros Therapeutics, Inc. NASDAQ (KROS) |
Treatment for hematological disorders | Jefferies SVB Leerink Piper Sandler |
04/07/2020 S-1 |
$16.00 | $110.40 million |
$14.00- $16.00 |
|
| Zentalis Pharmaceuticals, Inc. NASDAQ (ZNTL) |
Small molecule cancer therapies | Morgan Stanley Jefferies SVB Leerink Guggenheim |
04/02/2020 S-1 |
$18.00 | $190.02 million |
$16.00 – $18.00 |
|
| IMARA Inc. NASDAQ (IMRA) |
Therapies for hemoglobinopathies | Morgan Stanley Citigroup SVB Leerink |
03/11/2020 S-1 |
$16.00 | $86.48 million |
$16.00 – $18.00 |
|
| Passage Bio, Inc. NASDAQ (PASG) |
CNS disorder therapies | J.P. Morgan Goldman Sachs Cowen & Co. |
02/27/2020 S-1 |
$18.00 | $248.4 million |
$16.00 – $18.00 |
|
| Revolution Medicines, Inc. NASDAQ (RVMD) |
Protein therapies to treat cancer | J.P. Morgan Cowen & Co. SVB Leerink Guggenheim |
02/12/2020 S-1 |
$17.00 | $273.7 million |
$14.00- $16.00 |
|
| Beam Therapeutics, Inc. NASDAQ (BEAM) |
Gene Editing | J.P. Morgan Jefferies Barclays Capital |
02/05/2020 S-1 |
$17.00 | $207 million |
$15.00 – $17.00 |
|
| PPD, Inc. NASDAQ (PPD) |
Drug development & laboratory svcs | Barclays Capital J.P. Morgan Morgan Stanley Goldman Sachs |
02/05/2020 S-1 |
$27.00 | $1.80 billion |
$24.00 – $27.00 |
|
| 1Life Healthcare NASDAQ (ONEM) |
Digital healthcare platform | J.P. Morgan Morgan Stanley |
01/30/2020 S-1 |
$14.00 | $281.00 million |
$14.00 – $16.00 |
|
| Arcutis Biotherapeutics, Inc. NASDAQ (ARQT) |
Treatments for dermatological diseases | Goldman Sachs Cowen & Co. Guggenheim |
01/30/2020 S-1 |
$17.00 | $183.28 million |
$15.00 – $17.00 |
|
| Black Diamond Therapeutics NASDAQ (BDTX) |
Small molecule tumor-agnostic therapies | J.P. Morgan Jefferies Cowen & Co. |
01/29/2020 S-1 |
$19.00 | $231.3 million |
$16.00 – $18.00 |
Issuer |
| I-Mab NASDAQ (IMAB) |
Drugs for cancers & autoimmune diseases | Jefferies China International Capital Corporation |
01/16/2020 F-1 |
$14.00 | $119.25 million |
$12.00 – $15.00 |